ImmuPharma PLC
LSE:IMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ImmuPharma PLC
Long-Term Debt
ImmuPharma PLC
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImmuPharma PLC
LSE:IMM
|
Long-Term Debt
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Long-Term Debt
£14.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Long-Term Debt
$26.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Long-Term Debt
$1.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Long-Term Debt
£58.2m
|
CAGR 3-Years
92%
|
CAGR 5-Years
42%
|
CAGR 10-Years
45%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Long-Term Debt
£95.1m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
17%
|
|
ImmuPharma PLC
Glance View
ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. The firm is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The firm's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The firm's research operations are in France.
See Also
What is ImmuPharma PLC's Long-Term Debt?
Long-Term Debt
0
GBP
Based on the financial report for Jun 30, 2025, ImmuPharma PLC's Long-Term Debt amounts to 0 GBP.
